Wacker Biotech B.V. – FDA 483, Nov 21, 2025
An FDA inspection of Wacker Biotech B.V. in Amsterdam, Netherlands, a drug substances manufacturer, revealed significant deficiencies in quality control and manufacturing processes. Observations included issues with endotoxin testing sample containers, inaccurate electronic data reconciliation, inadequate laboratory procedures for biological indicators, and failure to follow environmental monitoring protocols. Additionally, equipment cleaning procedures were found to be insufficient, posing a risk of contamination in classified production areas.
ID · 9c4c66cf-ec5e-4dbb-9586-45f2537debe2
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.